After being interrogated for more than four hours by members of a congressional committee, Mylan CEO Heather Bresch still did not explain why the company had significantly raised the price of its EpiPen over the past several years.
Since Mylan acquired the EpiPen from Merck in 2007, it raised the price of the EpiPen to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007.
According to a MedScape article, Bresch expressed regret about the controversy. "I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the full wholesale acquisition cost price or more," she said. "We never intended this."
Read the full story